This searing indictment, David HealyOCOs most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles problems in health care that are leading to a growing number of deaths and disabilities. Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system.

The period from the late seventeenth to the early nineteenth century-the so-called long eighteenth century of English history-was a time of profound global change, marked by the expansion of intercontinental empires, long-distance trade, and human enslavement. It was also the moment when medicines, previously produced locally and in small batches, became global products. As greater numbers of British subjects struggled to survive overseas, more medicines than ever were manufactured and exported to help them. Most historical accounts, however, obscure the medicine trade's dependence on slave labor, plantation agriculture, and colonial warfare. In Merchants of Medicines, Zachary Dorner follows the earliest industrial pharmaceuticals from their manufacture in the United Kingdom, across trade routes, and to the edges of empire, telling a story of what medicines were, what they did, and what they meant. He brings to life business, medical, and government records to evoke a vibrant early modern world of London laboratories, Caribbean estates, South Asian factories, New England timber camps, and ships at sea. In these settings, medicines were produced, distributed, and consumed in new ways to help confront challenges of distance, labor, and authority in colonial territories. Merchants of Medicines offers a new history of economic and medical development across early America, Britain, and South Asia, revealing the unsettlingly close ties among medicine, finance, warfare, and slavery that changed people's expectations of their health and their bodies.

Gary Gereffi first explains how foreign corporations took over the flourishing Mexican steroid industry in the 1950s and 1960s and thwarted the country's later attempts to establish a more equitable distribution of industry benefits. In this valuable theoretical contribution Professor Gereffi uses the Mexican industry's plight as a crucial-case test for dependency theory Originally published in 1983. The Princeton Legacy Library uses the latest print-on-demand technology to again make available previously out-of-print books from the distinguished backlist of Princeton University Press. These editions preserve the original texts of these important books while presenting them in durable paperback and hardcover editions. The goal of the Princeton Legacy Library is to vastly increase access to the rich scholarly heritage found in the thousands of books published by Princeton University Press since its founding in 1905.

Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies inresearch and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy.

Experiments on patients, processes or plants all have random error, making statistical methods essential for their efficient design and analysis. This book presents the theory and methods of optimum experimental design, making them available through the use of SAS programs. Little previous statistical knowledge is assumed. The first part of the book stresses the importance of models in the analysis of data and introduces least squares fitting and simple optimum experimental designs. The second part presents a more detailed discussion of the general theory and of a wide variety of experiments. The book stresses the use of SAS to provide hands-on solutions for the construction of designs in both standard and non-standard situations. The mathematical theory of the designs is developed in parallel with their construction in SAS, so providing motivation for the development of the subject. Many chapters cover self-contained topics drawn from science, engineering and pharmaceutical investigations, such as response surface designs, blocking of experiments, designs for mixture experiments and for nonlinear and generalized linear models. Understanding is aided by the provision of "SAS tasks" after most chapters as well as by more traditional exercises and a fully supported website. The authors are leading experts in key fields and this book is ideal for statisticians and scientists in academia, research and the process and pharmaceutical industries.

Ernest Solvay, philanthropist and organizer of the world-famous Solvay conferences on physics, discovered a profitable way of making soda ash in 1861. Together with a handful of associates, he laid the foundations of the Solvay company, which successfully branched out to other chemicals, plastics, and pharmaceuticals. Since its emergence in 1863, Solvay has maintained world leadership in the production of soda ash. This is the first scholarly book on the history of the Solvay company, which was one of the earliest chemical multinationals and today is among the world's twenty largest chemical companies. It is also one of the largest companies in the field to preserve its family character. The authors analyze the company's 150-year history (1863 2013) from economic, political, and social perspectives, showing the enormous impact geopolitical events had on the company and the recent consequences of global competition."

Gary Gereffi first explains how foreign corporations took over the flourishing Mexican steroid industry in the 1950s and 1960s and thwarted the country's later attempts to establish a more equitable distribution of industry benefits. In this valuable theoretical contribution Professor Gereffi uses the Mexican industry's plight as a crucial-case test for dependency theory Originally published in 1983. The Princeton Legacy Library uses the latest print-on-demand technology to again make available previously out-of-print books from the distinguished backlist of Princeton University Press. These editions preserve the original texts of these important books while presenting them in durable paperback and hardcover editions. The goal of the Princeton Legacy Library is to vastly increase access to the rich scholarly heritage found in the thousands of books published by Princeton University Press since its founding in 1905.

Key Account Management Excellence in Pharma & Medtech is designed to help life sciences practitioners develop and execute innovative and effective key account management (KAM) strategies and capabilities. Pharmaceutical and medtech companies are increasingly pursuing KAM in response to the rapid rise of large, sophisticated and complex healthcare provider and payer systems and groups. Those that invest the time to get KAM right will protect their business and grow with these rising customers. This book is groundbreaking in both its scope and its tailoring of leading KAM practices specifically for life sciences. The central theme is that "key account management is an organization-wide business strategy, not just a role or a sales-specific initiative." KAM is a strategy focused on providing unique offerings and value through an orchestrated, cross-functional, go-to-market model designed specifically to address the needs and engagement preferences of a unique segment of customers. The insights and practices shared in this book are designed to be a valuable reference at every stage of the KAM journey. The book has been designed to facilitate a common language and deep understanding of KAM issues and leading practices organization-wide-particularly for life sciences leaders, account managers and cross-functional team members responsible for building, transforming and supporting their organization's KAM strategies and capabilities.

The pharmaceutical industry is broken. From the American hedge fund manager who hiked the price of an AIDS pill from $17.50 to $750 overnight to the children's cancer drugs left intentionally to expire in a Spanish warehouse, the signs of this dysfunction are all around. A system that was designed to drive innovation and patient care has been relentlessly distorted to drive up profits. Medicines have become nothing more than financial assets. The focus of drug research, how drugs are priced and who has access to them is now dictated by shareholder value, not the good of the public. Drug companies fixated on ever-higher profits are being fined for bribing doctors and striking secret price-gouging deals, while patients desperate for life-saving medicines are driven to the black market in search of drugs that national health services can't afford. Sick Money argues that the way medicines are developed and paid for is no longer working. Unless we take action we risk a dramatic decline in the pace of drug development and a future in which medicines are only available to the highest bidder. In this book investigative journalist Billy Kenber offers a diagnosis of an industry in crisis and a prescription for how we can fight back.

In pharmaceutical patent law, the problem of lack of policy direction and inappropriate legal framework is widespread - particularly among jurisdictions with little to no pharmaceutical research or manufacturing. This book aims to inform public policy and influence debate through a comprehensive review of Hong Kong's pharmaceutical patent law. By demonstrating the need for a holistic review of pharmaceutical patent laws and evaluating Hong Kong's system in light of health policy, economic and social factors, Bryan Mercurio recommends changes to the legal framework and constructs a more efficient and effective system for Hong Kong. He thoroughly evaluates the international framework and best practice models to offer a global perspective to each issue before providing local context in the analysis. While the focus of the book is Hong Kong, the analysis on pharmaceutical patent law and policy extends to other jurisdictions facing issues on reforming their national system.

Photophysics and Nanophysics in Therapeutics explores the latest advances and applications of phototherapy and nanotherapy, covering the application of light, radiation, and nanotechnology in therapeutics, along with the fundamental principles of physics in these areas. Consisting of two parts, the book first features a range of chapters covering phototherapeutics, from the fundamentals of photodynamic therapy (PDT) to applications such as cancer treatment and advances in radiotherapy, applied physics in cancer radiotherapy treatment, and the role of carbon ion beam therapy. Other sections cover nanotherapeutics, potential applications and challenges, and nanotherapy for drug delivery to the brain. Final chapters delve into nanotechnology in the diagnosis and treatment of cancers, the role of nanocarriers for HIV treatment, nanoparticles for rheumatoid arthritis treatment, peptide functionalized nanomaterials as microbial sensors, and theranostic nanoagents.

There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that the pharmaceutical industry is both socially beneficial and profitable. Regulators are expected to ensure that the economic success of the industry does not come at the expense of public safety, yet they have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between the pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.

"How do you market a successful brand in today's constantly changing healthcare industry? Markus Saba and Hilary Gentile have spent decades confronting that challenge. In Brand Plan Rx, they show us how to use a simple and powerful framework of inspirational storytelling." -Arianna Huffington, founder and CEO, Thrive Global Build a healthcare brand that changes lives. A thriving brand requires a plan. Even the best marketing ideas cannot come to fruition without a cohesive brand plan. This is especially relevant and challenging in the health and wellness industry. Brand Plan Rx provides a proven road map that empowers you to make the choices that drive demand and will get you to synthesize your plan onto one page designed specifically with the health and wellness industry in mind. In Brand Plan Rx, healthcare and pharmaceutical marketing executives, professor Markus Saba and marketer Hilary Gentile, provide a step-by-step formula to uncover the unique needs that drive brand choice in the health and wellness industry. Drawing on their decades of work in launching major pharmaceutical and wellness brands, they outline exactly how you can create a strong, effective brand plan to launch and market your brand. Brand Plan Rx's Choice Map guides you through the difficult decisions that will build your brand. You will bring it all together into a cohesive and clear brand story. As you master synthesis and clarity, you will create a one-page Cohesion Map, a clear roadmap to use as your sounding board for all decisions you make for your brand. Ultimately, you'll learn how to apply traditional marketing principles to the healthcare space so that your brand will make a marked difference in people's lives. "Captures the essence of brand planning in the pharma/biotech space in a manner that is clear, simple, and practical." -Enrique Conterno, CEO, FibroGen, Inc. "A book that considers all the distinct factors of marketing in the healthcare industry. Practical, to the point, entertaining, and educational." -Rolf Hoffmann, chairman of the board of directors, Biotest "I recommend this book to all commercial leaders in our industry." -Burcu Eryilmaz, VP, Sanofi Genzyme "An essential guide from industry experts who have spearheaded thousands of successful launches." -Danielle Kayembe, founder and CEO, GreyFire Impact